-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 NBkRfTJc0b/7dPiQuH7q48zkn3z1SoVnHbtA9/q62If7GdwPbBG6xQlJr2SJr6z0
 75Ruia2FClrx7PBeAX8l6A==

<SEC-DOCUMENT>0000950153-06-000594.txt : 20060307
<SEC-HEADER>0000950153-06-000594.hdr.sgml : 20060307
<ACCEPTANCE-DATETIME>20060307170747
ACCESSION NUMBER:		0000950153-06-000594
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20060307
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20060307
DATE AS OF CHANGE:		20060307

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ORTHOLOGIC CORP
		CENTRAL INDEX KEY:			0000887151
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				860585310
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21214
		FILM NUMBER:		06670756

	BUSINESS ADDRESS:	
		STREET 1:		1275 WEST WASHINGTON STREET
		CITY:			TEMPE
		STATE:			AZ
		ZIP:			85281
		BUSINESS PHONE:		6024375520

	MAIL ADDRESS:	
		STREET 1:		1275 WEST WASHINGTON STREET
		CITY:			TEMPE
		STATE:			AZ
		ZIP:			85281
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>p71991e8vk.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 20%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>Pursuant to Section&nbsp;13 or 15(d)<BR>
of the Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center"><DIV style="font-size: 3pt; margin-top: 16pt; width: 20%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Date of Report: March&nbsp;7, 2006<BR>
(Date of earliest event reported)
</DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>ORTHOLOGIC CORP.</B>
</DIV>

<DIV align="center"><DIV style="font-size: 3pt; margin-top: 1pt; width: 100%; border-top: 1px solid #000000">&nbsp;</DIV></DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top">Delaware
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">000-21214
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">86-0585310</TD>
</TR>
<TR style="font-size: 1px">
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of<BR>
incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer<BR>
Identification No.)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="36%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">1275 West Washington Street, Tempe, Arizona
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">85281</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top" style="border-top: 1px solid #000000"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(Address of principal executive offices)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(Zip Code)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">Registrant&#146;s telephone number, including area code:<BR>
(602)&nbsp;286-5520
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR
230.425)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR
240.14a-12)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;8 &#151; Other Events</B>
</DIV>

<!-- link2 "Item&nbsp;8.01 Other Events." -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;8.01 Other Events.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;7, 2006, OrthoLogic Corp. issued a press release announcing revised guidance for the
expected release of topline results from its Phase 3 clinical trial of Chrysalin<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> (TP508) in
fracture repair. Management now expects to communicate topline results by March&nbsp;31, 2006, which is
revised from previously provided guidance of April&nbsp;30, 2006. A copy of the press release is
attached hereto as Exhibit&nbsp;99.1 and is incorporated by reference herein.
</DIV>

<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Section&nbsp;9 &#151; Financial Statements and Exhibits</B>
</DIV>

<!-- link2 "Item&nbsp;9.01 Financial Statements and Exhibits." -->

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(d)&nbsp;Exhibits
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="8%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="88%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press release dated March&nbsp;7, 2006</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "SIGNATURES" -->

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="44%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dated: March&nbsp;7, 2006
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">ORTHOLOGIC CORP.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">/s/ Dr.&nbsp;James M. Pusey
<DIV style="font-size: 1pt; border-top: 1px solid #000000">&nbsp;</DIV>
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">James M. Pusey</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>p71991exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><DIV style="border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV>
</DIV>

<P><DIV style="position: relative; float: left; width: 60%">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><IMG src="p71991p7199100.gif" alt="(ORTHOLOGIC LOGO)">
</DIV>

</DIV>
<DIV style="position: relative; float: right; width: 38%">

<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B><FONT style="font-variant: SMALL-CAPS">1275 W. Washington St.</FONT><BR>
<FONT style="font-variant: SMALL-CAPS">Tempe, AZ 85281</FONT><BR>
<FONT style="font-variant: SMALL-CAPS">(602)&nbsp;286-5520</FONT></B><BR>
<U>www.orthologic.com</U><BR>
<B><FONT style="font-variant: SMALL-CAPS">Nasdaq</FONT>: OLGC</B>
</DIV>

</DIV>
<BR clear="all"><BR>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="68%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">FOR FURTHER INFORMATION:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Lauren Tortorete (media)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Melanie Friedman (investors)</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Biosector 2
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Stern Investor Relations</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">(212) 845-5609
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">(212) 362-1200</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">ltortorete@biosector2.com
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">melanie@sternir.com</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ORTHOLOGIC UPDATES GUIDANCE FOR RELEASE OF PHASE 3 RESULTS<BR>
FOR CHRYSALIN<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> IN FRACTURE REPAIR</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>TEMPE, AZ., March&nbsp;7, 2006 &#151; OrthoLogic Corp. (NASDAQ: OLGC) </B>today announced revised guidance for
the expected release of topline results from its Phase 3 clinical trial of Chrysalin<SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP> (TP508) in
fracture repair. Management now expects to communicate topline results by March&nbsp;31, 2006, which is
revised from previously provided guidance of April&nbsp;30, 2006.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>About OrthoLogic<BR></B>
OrthoLogic is a biotechnology company focused on the development and commercialization of the novel
synthetic peptide Chrysalin<SUP style="font-size: 85%; vertical-align: text-top"><SUP style="font-size: 85%; vertical-align: text-top">&#174;</SUP></SUP> (TP508) in two lead indications, both of which represent
areas of significant unmet medical need &#151; fracture repair and diabetic foot ulcer healing. Based
on the Company&#146;s pioneering scientific research of the natural healing cascade, OrthoLogic has
become a leading company focused on tissue and bone repair. The Company owns exclusive worldwide
rights for Chrysalin.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">OrthoLogic is committed to developing a pipeline of novel peptides and other molecules aimed at
helping patients with equally under-served conditions. The Company has an exclusive worldwide
license to the novel pre-clinical 24-amino acid peptide AZX100, the first of a new class of
compounds in the field of smooth muscle relaxation called Intracellular Actin Relaxing Molecules,
or ICARMs&#153;. AZX100 is currently being investigated for medically and commercially significant
applications, such as the treatment of vasospasm associated with subarachnoid hemorrhage, the
prevention of keloid scarring and the treatment of asthma.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">OrthoLogic&#146;s corporate headquarters are in Tempe, Arizona. For more information, please visit the
Company&#146;s Web site: <u>www.orthologic.com</u>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>Statements in this press release or otherwise attributable to OrthoLogic regarding our
business that are not historical facts are made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These forward-looking statements, which include
the timing and acceptability of FDA filings and the efficacy and marketability of potential
products, involve risks and uncertainties that could cause actual results to differ materially from
predicted results. These risks include: delays in obtaining or inability to obtain FDA,
institutional review board or other regulatory approvals of preclinical or clinical testing;
unfavorable outcomes in our preclinical and clinical testing; the development by others of
competing technologies and therapeutics that may have greater efficacy or</I>
</DIV>
<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>lower cost; delays in obtaining or inability to obtain FDA or other necessary regulatory approval
of our products; our inability to successfully and cost effectively develop or outsource
manufacturing and marketing of any products we are able to bring to market; changes in FDA or other
regulations that affect our ability to obtain regulatory approval of our products, increase our
manufacturing costs or limit our ability to market our products; our possible need for additional
capital in the future to fund the continued development of our product candidates; and other
factors discussed in our Form 10-K for the fiscal year ended December&nbsp;31, 2004 our Form 10-Q for
the quarter ended September&nbsp;30, 2005, and other documents we file with the Securities and Exchange
Commission.</I>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">###
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Editors&#146; Note: This press release is also available under the Investors section of the Company&#146;s
website at: <u>www.orthologic.com</u>.
</DIV>



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>p71991p7199100.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 p71991p7199100.gif
M1TE&.#EAN`%/`/<``````(````"``("`````@(``@`"`@,#`P,#<P*;*\`0$
M!`@("`P,#!$1$186%AP<'"(B(BDI*55554U-34)"0CDY.?]\@/]04-8`D\SL
M_^_6QN?GUJVID#,``&8``)D``,P````S`#,S`&8S`)DS`,PS`/\S``!F`#-F
M`&9F`)EF`,QF`/]F``"9`#.9`&:9`)F9`,R9`/^9``#,`#/,`&;,`)G,`,S,
M`/_,`&;_`)G_`,S_````,S,`,V8`,YD`,\P`,_\`,P`S,S,S,V8S,YDS,\PS
M,_\S,P!F,S-F,V9F,YEF,\QF,_]F,P"9,S.9,V:9,YF9,\R9,_^9,P#,,S/,
M,V;,,YG,,\S,,__,,S/_,V;_,YG_,\S_,___,P``9C,`9F8`9ID`9LP`9O\`
M9@`S9C,S9F8S9IDS9LPS9O\S9@!F9C-F9F9F9IEF9LQF9@"99C.99F:99IF9
M9LR99O^99@#,9C/,9IG,9LS,9O_,9@#_9C/_9IG_9LS_9O\`S,P`_P"9F9DS
MF9D`F<P`F0``F3,SF68`F<PSF?\`F0!FF3-FF68SF9EFF<QFF?\SF3.9F6:9
MF9F9F<R9F?^9F0#,F3/,F6;,9IG,F<S,F?_,F0#_F3/_F6;,F9G_F<S_F?__
MF0``S#,`F68`S)D`S,P`S``SF3,SS&8SS)DSS,PSS/\SS`!FS#-FS&9FF9EF
MS,QFS/]FF0"9S#.9S&:9S)F9S,R9S/^9S`#,S#/,S&;,S)G,S,S,S/_,S`#_
MS#/_S&;_F9G_S,S_S/__S#,`S&8`_YD`_P`SS#,S_V8S_YDS_\PS__\S_P!F
M_S-F_V9FS)EF_\QF__]FS`"9_S.9_V:9_YF9_\R9__^9_P#,_S/,_V;,_YG,
M_\S,___,_S/__V;_S)G__\S___]F9F;_9O__9F9F__]F_V;__Z4`(5]?7W=W
M=X:&AI:6ELO+R[*RLM?7U]W=W>/CX^KJZO'Q\?CX^/_[\*"@I("`@/\```#_
M`/__````__\`_P#______RP`````N`%/```(_@#_"1Q(L*#!@P@3*ES(L.%"
M>PXC2IQ(L:+%BQ@S:MS(L:-'A?8@?AQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-
MFPCKU<.Y,:3/C#MY"AT:,2C1HRI_;M2)M*G3IU"C\O0I4JK5JUBS:G6IU*%1
M@DR_SM2IDY[.JA>9'A2[M>W$>F;_?54KUZU;>F;)PK6HMZ_?OX`#"PZ,D:[=
MPQCQHBU(5B!;Q$[+BDNP:U<"<7$?-RXX+P'ERJ!#BQY-NK3ITZ`SI`TZEV#(
MNI!C#[3WV&!MV4+)[HH$:1&DWPGHR;T]4'<<`X&2*U_.O+GSY]"5__X=:#HD
M`[/$4?2+5YSW[YMQ_L>>YUAXW(%Y#8LGJE/<[DB7)P,7#GMAO?>S\NO?S[^_
M__\``O@;+9#H0I]"]:"U$UP94*8++?K1HDME&>"U'F)EZ>586>D9U=6%-.F4
M0(&8X56/.+K`1QQ!YF4@3@8PQBCCC#36:..-.,9X'DB+U9/!;M8%.>`N\#@&
MXE8_1D)+:9U$L@MY'KYV9(@9*/GB+@@<P(N/D.RB77VUJ9>0F!IV%!Y#2EDX
MV2Q!TN)FD&P6F,&"4DX)596^03)+(&SR&><NJJVXEJ`Y9;080V(>.EM*]T7B
M(F^\04(+E[O\$T]]A6**4)VN<5K1A__0!A%Q(>TDG(^Z7#>++O&5Z%T"_KK$
M^6=>]"AJYU`^PJJG+++,PFN!@)IZ:T=U$EH0/9'H@IF3WNWVJ"Y[+61AJ&AZ
M&BI5V&:K+54)HD6;7`<>5)59&1!8X&4=FGAB!JGR"9QV"3)EK4"V,C853O6"
M!5<XJ<K"9Z^0N+C@L,2^9NRQ7>JTI$Y5SIFJ.(+2=Z9M?@TZ&&##T:77C@C2
MLPLDU7$#<:<^P077QWI6IXMJY=6T[;9O'4P3N2#G%T@N"927X'8RV]7S0N(L
MLB6*N]`S623PW!<PM9H6]*-G4$<M]=145VWUU5$'VQ`](^KIY8)G91L4UWKN
M*2?83^5K7U3SG)BJS<J:1=5V!#>=5@:0)(UB_I<I1B+<B*JI+1?*9?\GY.&(
M)WYX?HA#VY`X!,ZRRTZEAGMMJ!F&4_9ODT]+\<10_6RW2N;)-:*[!F(KF^!T
M\R@1WO*X#0EO*],<.**$*Z[[[KSK">=TRC)$CR[857IY1%RS:7;.4'Y.&X>9
M@7[J/^HV5C'8&`^GV%XFEVJJQ#F!S2WX;)U7)GKIC6Z;./\FO%1Q1DU<Z[6L
MNZ:6R1U2/O=PQ157O:EL&1MKP`(N[O"/('@+U(3$T0G'-4HU\QB50AJ4HQPE
MH((8K%$"PD%!!`V.32OKED3,LK?DR$E3?3$2^EBS&0L="'3Z"DL*31:V:)U/
M?1J[GPPSQAC6O$A&_I@!H`H9PCY?N6\DK*$'C8(HPHB4;&/0.X\]:B6O4<5/
M8Z=JC7JL"!<FW@\AXDB8/";D,4?MQ%E,LX^8/L>2L'`,<[#)P)YFD;/Y'2PO
M>)..\?25O@TQ"$;R"%=8^%>/>7C18F0ZT8O,0@]Y($!@?<E`VX;HOSYF;$XQ
MA)]<&J2+5`VHDU_+&*&**(LC+F5^<IE,)V4%2HB1Y8T)F>(K)[.+![EI0A>\
MHB:I!\G^>0Z12G20FR1DF0H-C#$%PLN$"NDDG30S@F@22*U>MJUIE@6)D]Q4
M7=B5'`-]L2%GT<DN]E3*I<%O%VPP`"1R$:?%32@<(R.+%?$&I_P,TTWM_IS%
M/<WUFT5XJ4H#&F:<%F%&BB$@$FQ89RYRT<G?L.%)"$+5;]1I'8J>RWHK(J4I
M@>+#W#4.D@=K#[]TQRI,JF<>A.//@%C6P_:P*U*(`]3("/BQRSBI;<X:4:4Z
MM):"4/-EF_2.B[Y#U*(:]3M#32HL?2JBW]#Q'^2)V13_L;=>!<*;Q6'7=!CG
MU)ABDI'#&5%_MKHYI[;3.B:<7)*V>E:M6<Y'0)+.=.!SH*HP13Z_F=`N@A$.
M!P4IEP:ITZC"R+C)::1.7",>L(KIF5WP<U637*-M?O2G5L%(5WD-SIE0VBX_
MF0T2%[38CX!W0:0Z=CI:<YJ$Q(&`24ZF2BNK_LMMT%81N"2`%LG:IVYWJ]M.
MWC.$E+S<B5`VJ4%*9&>#VUPN(&;7-?EIG8"ZK"=1:U+RF*5K3EWH?OA9N(5Z
M-Q<U.^&)3F<S21DSN*G4ZG,E9U+*B255!EC9G/KRHG9Q;J:=HE<J-V=8!<EL
M6F0K$#Q96A;*@@P2]XB'9`WBGNOH(ASFD\Q(Y[.6O17N7/C5%P,SZ\K9&(UP
ML=673L5AW9.QP47]2R/Z>'G4HPY5J.4J7(!FK)]><9460@VL+,6Z--$9!%F^
MRD_1J&=%)6[.I(Y1+YLZ!Q:4?:UB']N3LK@3X."E\F.RR,5569J04^UM>9:#
MXR:)1XL$$*<>_$(=_L1>B$KTM&^/B2&7)XLV6ZW&*5"VD<MKM-JE,(/%8]1A
M*"U.)3&RP>U+@>W.G/-R$')UPJE]#92I/@:?9A%HOKL,[,EZIS@:>SH_O`JR
M\KHT*(^9,%!V[=F"HMRKX!4+;XP+7+S&#`F`Y:S))U2Q0**\4;",*!+PTLD\
M(A&(4AK6*UC^#2:9*I"].2F+B^*?*M6L0D_1X\WO`S0D.,C#8S'H;2=\JS2I
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M1!?^FL6RU9AP=I((WEPR^``C6@\>X_TQ.#<V1ZITU12*2Y:5IPZI;2,<.5:'
M[H'GX\279C!P0:@ZF#X(/15_0\;D)0%S=+4T><JSDE/^BKD[>X#R[79=.X9P
M':<BW-^6]NE)\S[%OKR",`[>_OK=[4L%>0`7_M2P@L2JE(MWG3@89^7)ILK5
M(@GS"ZD*(39-2N:9'SU04,;E8WK8XA_3,B00#;_AY17:PN,VIR=<KF=$L7<L
M&-=G*18^U+,+?L)_?D0K'@06/K%^L+$BC91!&B@CC&0M$J5N@41D2S$B6I8?
M'39N#@A^&\(I"5!L@6!]]>`DZ'$0VO=CU`,7"&!_WV=.F4(0XN!X#F0;71,.
M?2=S.F1T$%>$QX)M0$%/;D=;/T9%I0<RFM=#IJ=X-TAO1J)M.?,:6=1^M/<8
M2(AT8](AA)4=3&<R\'-FC%$RJ9=B<($7Z2*'=%B'=GB'',(A4\48A"4+"^<1
M$J5_KO1"*8AW!Q%&_JT6%/8P#[P050E1@Q-1B%"79TZC'XYC)'<U'6^((`ZH
M97Y3.DN8<Q6A?$;C2?`B<SF1``;@+STF6\.S9`N8=`E'(&;&*?4`;DC6/,.3
M'%YB?('E:[\!@7!G/H@"5YUTC,B8C,JXC,RHC*D%%H35>2/A?[$6'M"G@EU6
M-N\7BP@!B1(AB1.H7^62'Y<H6R^7,&(A.+0!:[`7+V(1?SKG$':51]#29J\S
M1T<D$F=(8%XQ*A\S.;:(BP,#$<*A.<#11*\3C!^A%RYRAW:(5R!C0@*'./L1
MD=81<HXA5E?U$?Y8-H%`=[@&>T88(8J820;AC1$!CM&F3>.X*I-7%G%R_H(E
M^1!P@7$J(T0LPH03\2TZT2Z`5S^,P6OKYG$MF$P4(1P0H5/Z4QP"61]FX4G!
MXX@C]#'"R%&`-EV[DQQF9U;"=W8@4XY,66M^R)&[5FM[PF3%872&:!LDN9*2
MA9(.X8!L<FL>QY+M=XDL)$>S`Q>'HC;/8WFG&(I5N).#-1W"0C=[AX7H`94_
M(RSBT$QZ%I9[,B>T84WTH'^&)942`3@-5VJ18%&\LU"AQE43>3@2R2M6M8U@
M`2&]$H\:47KZT7F"Q&LLHQESA)&H*'A+]C-R"5JSD2\0T9)XN2'CE#"_1"_Y
M0A;NYINZ!H^?,BIBI0OCAI@8)V0(Q#A$R!=R_H$`21,VCO$V@4"9;V=ZH#5K
M$B$2/Q)^A[433X,:E:$+X/4O9@<PI>E4J%EC-Z-N`;0KDC,2Y"%'-C,IS?-R
M%*<ISW.;\<.-!`&7#=&;=.F+JD6.X.-Z!UE(GU>&<$$@K1F'@BE_YPD1)=2%
MU%-;T`="8,-KX@"4?B07\Y`_K-$OX6F>$-&;:Z:%)+-)T<(1.E0Q_:=$W%6?
MO2-TZ\.?KKD4D;.78$*;P06B[K(CA#(B[T81Y5:>83)N[`DAR<1""5>--IIG
M9H%E^MEH.ADS`,J<FX@@L,8F\^-_5U65.@JCXNF.!%(=2I@;R)DMR,E(#4(9
MG^&>?FH98`=VGE$A_D,:9$4*=Y$S"Y%@?]`GD@=4'$5)"_;"$%#Z@C\S7?7G
M(6,SHK"6I9B(>]A(HL*!`+6F;G[FG"1:IBQSI@HA#YN3HE0%7H]7$K>8,G%:
M@+^!D$(Q+]830SQJ)HVQA\71A_U)$O6@H;/C?,F%C5]4DP=)$96*FPRQ>K7X
M/&HA)2(D#I8`0E)D.C7#9;4UBZ$&KM(TIF\!H(K)JHWF=^[",F'T?YV)(.!Y
MJR>"I;.@JS?Q36/RGLW8K_[:KZE1J*U)JW?G-TDZ'?)0<FI!3U@U$='*FXPS
MB8,R$)W:L!W9INH#3M3(@SDIBGPA5KD@:]IYB^YB6'M7?,8ZK^XH$&4J_IUU
M=Q.9X1T.*8?O*I$RUI7^L3BHQ19]N)$C01L%JZQ*PR8)^RTB@2KQ19G06JK2
MNA#5*3DMUF(-`H3$R*;!TYE/Z3L22SWF>EQR&;)BMI-UP6LF>V`HBT0J^SS>
M2H['@Q.3]J_M=[,X.V-<:3-2IGZ[XK,?D;6E9+#Q`Z:UF560,B?J^G%,RYL/
MQT[[U!_:)2'D=Q["44(+)SJ;"IZXB:JUM0L&L%#:H:($]#<IXSAYA(Z]9Q]I
M.S91MBHWF!MN@QS-D3A]\ANH.;NT6[NVRRL!AU;K)(V,$0GI-FAZ-B\[V9-S
MM*A!*98E]2)^=39=IQ`/*Z5E)1W1X52XP*TE_OF*5Z6L)*J1`-FAAXHH;X.%
MVEL4S08\9S1XK+H7\D`A2.4>1?)"ITLM6*:ZPBL395%+_VJ3SQ61M]N__2M7
M%LFMML&:%-<MGBLNQ,LGT*(@6%9.]01<%_&\$]%9JY*_QUB"GKJ84A:8?,$E
M9_FR7.NQM=4OXINQ8U*^>76^NUD4]7``,!4D9UNKDSEK,VJ6TEF_,>%#KA08
M9TB:01(=0&Q"N0O#`?1]<]D]!ZQIV&M*JU:J;%5V=`1##2'!$C%=Z/)*+DI#
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MQS-LM'=L-K7'$RO2QW^<SZ>AGAD),N`58CA<%&'4I#NJEI2YB++SE75:EX]X
MN%*J?UN;9U=JO2R"K(&KG:$\QEWK%>/LFTQWE&EL6.KLDL>U395L'B]:_L?R
M'&5T*L4NL4,9(AA[]V\^#*3_QCD^)4V[6\`?S1=3V$U:FES*UK9Y-)<0NA#1
MW*`!%]$),8Y&R7"W&+%=>L(M>,SJH5%-BSN^`RU3[5/Z.!V$>CK@U;E'2:TH
M%+_>*JN=V]6Y>5BFPZ_-^*-R:],R1AWZH<;Y=:SXZ,QHO(;)=FSF0SBFO!-?
MEKT][1!)S1`.*C-.C9??0K9L'76L.#%832B*PFO>)#H_,;HCDT?@9<HL#&Y\
M#1:S[,$%7%L!W<$H@AQ"PB?)P29F-[=S:V.\>[RNS=7Q2BWC/`OA@!ZL(=BZ
MO2"X%W"`M[3^DM4)L=BO@Z5_:!1(N*CQ>A_^_A*$/OAF#<=CV9&CA"EXU1$7
M6^R"(BK.9FT8,ARCHA*<_#6='WH2C2+7<\4;][D?_CO?](T+["1EFN%N(AFO
M4\5-&/M\QP?68M8>U(?7QFVI%*'<$='8F4&QX<5<%D&0TURDE0W&>IF$A9O3
MC<K5?N?0UUR,X[UQ*MTMLK/.4$7,C&(TX<,E`S?$=!V1!">M;A-DO?:<W.T^
M.#FTK"=#H2>K9'C4`Y'8"Z'@#B&<4@2B1XJRJD95L=8T%6X17T:Z8+R+Y5DJ
M8*I[H1VQCRH7IQL23UELJU+<.V<283)I^&O!:`ZPK`+"ST?"_XT1KV'0C1'8
MOB-K69=PU6G@*]G0_L?-F^["U`AAY"R4M3>Y&N@<1`QFW3%#Q_X"O-KY@R)I
MY?P9.$!)O$9-WEV.T"F8'X"N<F0YHBJ'Q=##RX/1'3)K(HLHT=RDY?G3$$8[
M*O>MFOW3T;<*J:*&=&Q^D@X=B7\^$>4RW?S7D0!#J#$#ND8YD,VVT93H&"U*
M/>*PN:<7V;+UR+KG(^2$X!/!IKXI%N4MGI>31]4Q9*FJW<,(A0@R#S$2=NI.
M->'0[GTUJ/:(@&!N;KX'$O2RQF;#SPMB7[5.L;20GW_(T-VXZ]_8Z\L-[`2$
MRM'G=G:%*.#B21?--%@]0N+TOO407D/W%@V&X]L,\!FV-3OHS(PQR\W6_EGE
M=Z[WD.%>H3T7PS4O_.*]4V9(386PZ$>J9I,N*]'\OK*X-D<=5S]"KA`.ZNNT
M,-U(.43@-F4()XNF%_#RDNPBK')54BDJO&5\H57K!GSK1,XWK^7<'K]9Q-)4
MFNT/M)`G\Z?<$)^S<-^RW95,?#F1>W+_3!^,%DW"_:WR>F#][N#4EMJ"U^<)
M;O`+7O1&Z2E%79Z8*#S7!1PCRNT9H.P)@2+^-!#C=W64VW-L<?@G#_)>/_(C
MWO@)YY%*?UPOI?+%6+-!K)6YX"^UF_I!C+O*X2_9"S]>R##@93:&-=5J&V-/
MI9GPP^]AV_.[>=@##_B\;M3+K3)(><TOI]8#_B,H#$,@CE/W#A?U1$1_8$."
MCGI<*/+F3>:"'-\0[2SRI/WYC5%5T9[@[CR-6+H[L>E9RG-6,%]6Y>B=PR$.
MW*`GLMKIOYA<&`L0].S](UB08#U=D`)!RE#/WD"#!3/,"D11%SV'$3423`!)
M5J!=]3:.++AK(:0$)$=FH`4)TL5_`^N)E#B+(J1=]/Z)I*ERYBZ7X7;^PPCQ
M8(:*LF8EZ$F2)E!(M#(4K3?QYBZ5)#NB;"IR7E5(-Z4.S4HP@\)9*,D61!@V
M4$.R-*M2Q!5H;%F#&2*]K*<3[]^"],1E(%S8L.&$@18J#JM0H6+(D25/9NP2
M<F.<33?6$Y=85M2&_O3FV9N9D>W,F#,3I,TESJ_1P'T3NF0ZSZ]!D?1VS5*Z
MM'1,HZAC_NMHL:]FC1`QSLJ5-ISPG<CG'13G,JHXX/0P$L0(=994U`\CEJ9)
M;ZLN[`</>JT'5-9GF!I_[^R<]J7.AS//!LK%4.3`AX([:+O.#$!OL[Z`8@PF
M>7`[3CC=Q,H@)K^TZPPRID0;3S>W<+HM.@AY^J=`2)Y##C`4G<I@%UUTH:5%
M6B)I<48::[3Q1AMIH667!LNJ*B&EHF+*GML"#&XF<<YCRK0-_\E`EY-RVBB_
M']\+1)?0'(+MH($2J.A*S9`;2+N=;'))RK(PJJ<XER84B#2VB$KLRH9&_C.*
MS.-V2J`E]$[4B;.6W@.M)^CZ>I(BQH;,CR@%VY0K0-PD2@C+$ZF;S:9=L*NT
MM(D,N)(IX';"Z,E`E$K@3_DZ"RNMG*"+[3B6[$LIQ9%D&HH\$,G[34U='Q3G
M5V"#%7;87[6ST#7RR%2)M#5UX2TM74`ER$@JD4S,M^@VTY.6D[!4CUHU.Q(T
MON&`8Y8@DRP2!U=M2UO-/F^YVS*P$1,R<\EL=X*(5&@G-"W`OOZL#I)(UD4.
MM35="I(OA*O*(`$6]^HP/F:M-<`E2G/5DKPG'55I5(G/-%C+AWCM^"6XQ`.N
M/84^\A9.!_6R;"F#J>UKIXX7VF5"E6EUZC=J_H,6D"ABBS;Z:&!=K77,CLWT
MT"!(CYJ-JVQ/_%%AG0V>MMIZ>5L(W[X`GHF>#')1JJ($UEU//IYB[0VED;<;
MC[/5WK-H*IYXJIC?0=DBLB!Q=MDKWH/UM.D]Q&UZD4;[%K(IEZ\)S;MI_L))
M+]5P9FM(:?5X2F"VBG9^-+HD9\N4IK\/VM.CCY;Z\#2P5IWE=.0"=_9,GN?U
MF=ZUL^H5J(NM$WYXXHLWWJ5(0BK+J)-/HB6!#%PS=K!=6EJ(TOF0,^]2LZ^'
M_O*XG)SSI02F$^BH<!2T&V/1G2J]Y;-Q2IMSG*$R&W)(<MD%U#]1O=HZ].!M
M;`]+B($V]SKN!&X6_@9X%F\29Q-$5>1P"U->F$2BJ@4)L"^_^IQ+P(,:!,H%
M9[=3RO.B=RP686PJ(,I+!TO5G.NML$D=^XC."/,KPE3O,:[;G8_JMPL@!E&(
M04Q`$8NX&]9)$()+9&(3G>@TS"@O*[:BV_C"D@L:]<<Q2_&77^B'@)`5+UZ]
M&Z%++A8)7N`F<,-;S$DB`8^UG*8CP;/,23*#((EYRCZ0../F\G4S#@FO14%L
MD75.%Z>8689X$;2C2Z"($]>PC28$%*0N@#@C0TYE.W(;":R0J!B;T`B`\R/C
M3J#B&.)AQ2"\J@H2A3>+&>T1EG`94*5\)A*6'$^7;GG@$WW91"5ZS4RJ_DQ1
M53I8QT8N1']J<]!(>"$C2QKQ<[I(7H\J];"([>(K>1'<CJ0),1?M(AY.@0>+
M]F?$B.D"`0CDCCG/"4YJ\N@_G5S1U(07O/;Y[IF#)&("PH'.2\)(1Y:DI8\H
M6;R+[<R+I?S8BOIS&>3MCYDD$=P@(7;)&+DC4K@AFPZ-MZ.",C1%U#I*2W9Y
MO$#@PFZ_9"D$>[/$YO"EAV2;IDE?$JWH-45WJ(.=@P+FHV3Y=#ZP*P])M/,;
M)#$S=1L::FFV62[UZ,M0]:31]T2$EP<U3"[9*PTG;3D>PDQS1CO#FWPVFIS`
M_.J?0(1>67TW5-\9-8=$M!Q21=C#3N(LK(<Y_DQ;PYJYQU!&L(.-3!T1=<<4
M<7)`@R&,TJ)6J_5L=:@]BVK/Q,3.T_CDK)F=4FJT6BG*AJHK1Y5<FD`[KRU1
MJ;/C$2I<?0):Q>:JF22!5*^0ZA,O"F<^NL.K4^)D6W:Q17`G)>Y)(R&MO\`5
M8+,ES6-]N"S:PBRZO(W-:HE$OWQMK98C45:H?*0R[*)(N@5);<56VUE=47=N
M0`7OHJ(:$:,\%FCJY:B6WA2TF_4VKB(26FWS1E2-`5?``W8M4,,CM-G>\CAJ
MXBR"2*8O;;$0:CNU)7932Y3MT'=IO/TJ=S;;VJZ>#Z\(T^][O7M=GU4L8(K=
M%*&$-A,-EWAL^:65FVX)?.->K<<>T^DM1(PT8D*=!K.LU:Y,;"P7TFK'N<L#
MV)+1&MDA=[(K6V6RY/Y%THBP$JNO+3"*@MO3#G/)LD86*5$_6^)BHEG-:V9S
MFW<79C?'6<YSIG.=[7QG/.=9SWOF<Y_]_&=`!UK0@R9TH0U]:$0G6M&+9G2C
C'?UH2$=:TI.F=*4M?6E,9UK3F^9TISW]:5"'6M1Z#@@``#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
